Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022–2024)

This study found high uptake of the first mpox vaccine dose and a high rate of second dose completion. Most participants made decisions aligned with public health guidance, though some underestimated their risk. With low vaccine coverage and natural immunity, Australia's 2024 mpox outbreak likely reflected insufficient population-level protection. Australia likely entered 2024 with little infection induced immunity because few cases had occurred in 2022-2023, and with incomplete vaccine coverage among people at ongoing risk. Our findings point to practical steps to prevent future outbreaks by increasing vaccination rates, including addressing side-effect concerns, streamlining vaccination, and improving awareness of personal risk factors.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2025-12-01
DOI
https://doi.org/10.1016/j.vaccine.2025.128041
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022–2024)

Michelle Giles, Fengyi Jin, Martin Holt, Anthony K J Smith et al.
Vaccine
Poxvirus research and outbreaks
article

Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022–2024)

Michelle Giles, Fengyi Jin, Martin Holt, Anthony K J Smith, Phillip J. Read, Benjamin R. Bavinton, Christopher Kincaid Fairley, Valérie Delpech, Richard D. Keane, Andrew Edwin Grulich, James MacGibbon, Anthony Dominic Kelleher, C. Raina MacIntyre, Mohamed Hammoud, Oskar Sachs
article en

Abstract

This study found high uptake of the first mpox vaccine dose and a high rate of second dose completion. Most participants made decisions aligned with public health guidance, though some underestimated their risk. With low vaccine coverage and natural immunity, Australia's 2024 mpox outbreak likely reflected insufficient population-level protection. Australia likely entered 2024 with little infection induced immunity because few cases had occurred in 2022-2023, and with incomplete vaccine coverage among people at ongoing risk. Our findings point to practical steps to prevent future outbreaks by increasing vaccination rates, including addressing side-effect concerns, streamlining vaccination, and improving awareness of personal risk factors.

VaccineVol. 70
UNSW Sydney (AU)
Australian Government
Openalex Percentile: Top 60%
Poxvirus research and outbreaks
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.